Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Neoplasm Staging. Found 180 abstracts

no pagination
Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European urology focus. 2019 Mar;5(2):242-9.   PMCID: PMC5712487
Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. Jama. 2018 Mar 06;319(9):896-905.   PMCID: PMC5885899
Roach M, Moughan J, Lawton CA, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1504-15.   PMCID: PMC6540797
Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol. 2018 Jan;41(1):59-64.   PMCID: PMC4769977
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-92.
Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr;123(7):1259-71.   PMCID: PMC5705038
Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE. Phase III Randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance). Journal of Clinical Oncology. 2017 Jul;35(19):2184-92.   PMCID: PMC5493050
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters M, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DS, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. The New England journal of medicine. 2017 Jun 08;376(23):2211-22.   PMCID: PMC5548388
Fortner RT, Schock H, Jung S, Allen NE, Arslan AA, Brinton LA, Egleston BL, Falk RT, Gunter MJ, Helzlsouer KJ, Idahl A, Johnson TS, Kaaks R, Krogh V, Lundin E, Merritt MA, Navarro C, Onland-Moret NC, Palli D, Shu XO, Sluss PM, Staats PN, Trichopoulou A, Weiderpass E, Zeleniuch-Jacquotte A, Zheng W, Dorgan JF. Anti-Mullerian hormone and endometrial cancer: a multi-cohort study. Br J Cancer. 2017 Oct 24;117(9):1412-8.   PMCID: PMC5672934
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Sep;3(9):1249-52.   PMCID: PMC5591751
Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017 Jan;18(1):31-41.   PMCID: PMC5476941
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul;123(13):2489-96.   PMCID: PMC5474197
Kantarjian HM, Roboz GJ, Kropf PL, Yee KW, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 Oct;18(10):1317-26.   PMCID: PMC5925750
Leclerc D, Pham DN, Levesque N, Truongcao M, Foulkes WD, Sapienza C, Rozen R. Oncogenic role of PDK4 in human colon cancer cells. Br J Cancer. 2017 Mar 28;116(7):930-6.   PMCID: PMC5379150
Rice TW, Ishwaran H, Hofstetter WL, Schipper PH, Kesler KA, Law S, Lerut EM, Denlinger CE, Salo JA, Scott WJ, Watson TJ, Allen MS, Chen LQ, Rusch VW, Cerfolio RJ, Luketich JD, Duranceau A, Darling GE, Pera M, Apperson-Hansen C, Blackstone EH. Esophageal Cancer: Associations With (pN+) Lymph Node Metastases. Ann Surg. 2017 Jan;265(1):122-9.   PMCID: PMC5405457
Skates SJ, Greene MH, Buys SS, Mai PL, Brown PH, Piedmonte M, Rodriguez GC, Schorge JO, Sherman M, Daly MB, Rutherford TJ, Brewster WR, O'Malley DM, Partridge EE, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek SM, Davidson SA, Edwards RP, Elg SA, Wakeley K, Phillips KA, Armstrong DK, Horowitz IR, Fabian CJ, Walker J, Sluss PM, Welch WR, Minasian L, Horick N, Kasten CH, Nayfield S, Alberts DS, Finkelstein DM, Lu K. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res. 2017 Jul 15;23(14):3628-37.   PMCID: PMC5726402
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Oct;15(10):1240-67.
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493-501.
Xu MJ, Chu C, Rubin S, Lin LL. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma. Am J Clin Oncol. 2017 Dec;40(6):598-604.   PMCID: PMC4733581
Beitler JJ, Quon H, Jones CU, Salama JK, Busse PM, Cooper JS, Koyfman SA, Ridge JA, Saba NF, Siddiqui F, Smith RV, Worden F, Yao M, Yom SS, Expert Panel on Radiation Oncology H, Neck. ACR Appropriateness Criteria((R)) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. Head & neck. 2016 Sep;38(9):1299-309.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Neoplasm Staging

Neoplasm Staging pathology Middle Aged Aged Male Female therapeutic use methods mortality Adult Disease-Free Survival Prognosis therapy adverse effects drug therapy Survival Analysis Neoplasm Invasiveness diagnosis Treatment Outcome administration & dosage surgery Follow-Up Studies Adenocarcinoma Drug Administration Schedule 80 and over Aged Neoplasm Grading Antineoplastic Combined Chemotherapy Protocols Combined Modality Therapy Survival Rate Chemoradiotherapy blood Lymph Node Excision United States Drug Dose-Response Relationship Retrospective Studies Risk Assessment Maximum Tolerated Dose Lymphatic Metastasis Prospective Studies Lymph Nodes etiology Squamous Cell Carcinoma Kaplan-Meier Estimate Patient Safety analogs & derivatives Prostatic Neoplasms Intravenous Infusions Cohort Studies epidemiology secondary Endometrial Neoplasms Head and Neck Neoplasms Monoclonal Antibodies Risk Factors genetics Intensity-Modulated Radiotherapy Proportional Hazards Models Radiotherapy Double-Blind Method Monoclonal Antibodies-Humanized Urinary Bladder Neoplasms Antineoplastic Agents statistics & numerical data Prostate-Specific Antigen Brachytherapy Case-Control Studies Progression-Free Survival Lung Neoplasms Transitional Cell Carcinoma Androgen Antagonists metabolism Propensity Score Neoplasm Metastasis Local Neoplasm Recurrence Carboplatin Tumor Biomarkers Adjuvant Chemotherapy Kallikreins Prostatectomy Carcinogenesis Flutamide Lymphedema Breast Neoplasms Adjuvant Chemoradiotherapy Early Detection of Cancer First-line chemotherapy human papillomavirus (HPV) transoral robotic surgery (TORS) Non-Small-Cell Lung Carcinoma Clinical Trials as Topic tonsillar cancer Machine Learning Canada Salvage Therapy Pancreatic Neoplasms Taxoids Incidence Dinoprostone Anilides postprostatectomy Young Adult Sarcoma Datasets as Topic chemotherapy Pyrroles Paclitaxel Sentinel Lymph Node Celecoxib biosynthesis Myeloid Leukemia-Acute Algorithms physiopathology Colonic Neoplasms Pharyngectomy Hysterectomy Practice Guidelines as Topic Kidney Neoplasms Papillomavirus Infections Postchemotherapy lymphadenectomy human papillomavirus Cultured Tumor Cells Predictive Value of Tests Internationality Pemetrexed immunology androgen deprivation National Cancer Institute (US) Gonadotropin-Releasing Hormone Postoperative Complications Abdominal Neoplasms Watchful Waiting docetaxel Hematologic Diseases urine enzymology Goserelin CA-125 Antigen Membrane Proteins Immunotherapy Molecular Targeted Therapy Academic Medical Centers Patient Selection Single-Blind Method Delphi Technique Conformal Radiotherapy Anti-Mullerian Hormone radiation Radiation Dose Fractionation Deoxycytidine Confidence Intervals
Last updated on Friday, January 03, 2020